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LETTERS TO THE EDITOR
Combination
renin-angiotensin system
blockade in hypertension
To the Editor: Wolf and Ritz recently reviewed the use
of an angiotensin-converting enzyme inhibitor (ACEI)
and angiotensin receptor blocker (ARB) combination,
and commented upon an additive effect on blood pres-
sure (BP) in some subjects receiving the combination
compared to monotherapy [1].
A recent meta-analysis of the effectiveness of an
ACEI-ARB combination in hypertension showed a 4/3
mm Hg fall in BP compared with ACEI or ARB
monotherapy [2]. Although this difference was statis-
tically significant, it is questionable whether it really
represents an additive effect because the studies upon
which this analysis was based predominantly used lower
doses of short-acting ACEIs, with measurement of BP
at trough or over 24 hours. Given that ARBs are gen-
erally longer-acting than ACEIs, it is not surprising that
an additive effect was seen. In the only study where a
long-acting ACEI (trandolapril) was given, there was
no additive effect of an ARB on BP [3]. Other studies
have shown that an ACEI-ARB combination may not
be more efficacious than monotherapy when the latter is
given at maximal dosage and at the correct frequency [4,
5]. Clearly, further studies need to be done using much
higher doses of ACEIs, with twice daily dosing for most
ACEIs, and measurement of BP at peak in addition to
trough.
None of the studies, except perhaps COOPERATE,
have really been of sufficient duration and size to deter-
mine the potential dangers of this treatment [3]. We agree
with the authors that it would be premature to recom-
mend the widespread use of an ACEI-ARB combination
until further safety studies have been done.
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CD4+CD25+ regulatory T
cells: A new treatment option
in glomerulonephritis
To the Editor: Future perspectives on the treatment
of glomerulonephritis (GN) were the subject of a re-
cent review article by Javaid and Quigg [1]. We totally
agree with the authors that new treatment options in GN
are needed. The authors mentioned diverse new aspects
of treatment, including antigen-specific therapy by us-
ing double-stranded DNA molecules, as well as blocking
effector systems by targeting complement factor C5 or
TNF-a receptor with antibodies. But still, the results are
not satisfying. Recently, our group provided compelling
evidence that CD4+CD25+ T cells, so called regulatory
T cells (Treg), could be a new therapeutic treatment op-
tion in GN. Treg were recently described to play a pivotal
role in the maintenance of tolerance in rodents and hu-
mans [2]. Several experimental models of organ-specific
autoimmune diseases provided evidence that Treg main-
tain self-tolerance and protect from the development of
autoimmune diseases [3].
In our experimental study using an anti-glomerular
basement membrane GN model [4], we demonstrated
that the transfer of Treg significantly decreased glomeru-
lar injury, reflected by decreased proteinuria and infiltra-
tion of inflammatory cells, like effector T cells, as well as
macrophages. Additionally, we provided evidence that
Treg seem to exert their immunosuppressive potential
in the draining lymph nodes of the kidneys, where the
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initiation of the immune response seems to take place.
These findings from a murine GN model suggest that the
transfer of in vitro expanded autologous Treg might rep-
resent a new treatment option in human GN.
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Aldosterone-mediated
endothelial remodeling and
oxidative stress
To the Editor: The recognition of the inflamma-
tory and profibrotic role of aldosterone in the patho-
physiology of cardiovascular disease, via its effect on
endothelial dysfunction, is of growing importance, as
demonstrated by the results of the recently concluded
Randomized Aldactone Evaluation Study (RALES)
[1], and the EPlerenone neuroHormonal Efficacy and
SUrvival Study (EPHESUS) [2]. These studies have,
in fact, indicated the reduction of aldosterone effects
through receptor blocking as additional benefit to pa-
tients with cardiovascular diseases.
In a paper published in the May issue Kidney Inter-
national, Oberleithner documented “in vitro” an aldos-
terone remodeling effect on human endothelium through
induction of cell stiffness due to a presumably aldosterone
induced oxidative stress via modulation of NAD(P)H ox-
idase [3]. We would like to provide further support to the
contention of a specific remodeling and profibrotic ac-
tion of aldosterone with the demonstration “ex vivo” in
human mononuclear cells, recently published by our lab-
oratory [4], that indicates that aldosterone has a direct
effect on oxidative stress through its ability to increase
the levels of p22phox, an important subunit of NADPH
oxidase, essential for superoxide anion generation. It, in
fact, functions as an integral subunit of the final electron
transport from NADPH to heme and molecular oxygen in
generating superoxide anions. The aldosterone-induced
increased level of PAI-1, a recognized profibrotic protein,
we have shown in the same study [4], may also provide a
direct link to the cardiovascular profibrotic and remod-
eling action of aldosterone. Our findings were further
strengthened by similar effects shown by glycyrrhetinic
acid [4], a constituent of licorice root, which is known to
have a direct mineralocorticoid-like effect [5]. Thus, the
report of Oberleithner [3] in combination with the results
of our study provides clear evidence for the aldosterone-
related vascular remodeling effects through its induction
of oxidative stress and oxidative stress-related profibrotic
molecules, such as PAI-1 [4].
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Screening for
microalbuminuria
In their recent contributions to Kidney International,
de Zeeuw [1], as well as de Jong and Brenner [2], argue
that primary prevention of cardiovascular and renal dis-
ease may be possible by lowering albumin excretion in
